Germany's Biotest buys Nabi unit for $185M

USA-based Nabi Biopharmaceuticals has entered into a definitive agreement with Germany's Biotest AG to sell its Nabi Biologics strategic business unit (SBU) to Biotest Pharmaceuticals Corp for $185.0 million.

Biotest has agreed to acquire the Biologics SBU's products, including Nabi-HB (hepatitis B immune globulin [human]), and other plasma business assets, including Nabi's state-of-the-art plasma protein production plant, and nine Food and Drug Administration-certified plasma collection centers across the USA. The deal will also include certain of Nabi's Corporate Shared Services group assets, its Boca Raton, Florida, headquarters and other facilities, as well as the assumption of certain liabilities.

"With the acquisition of Nabi Biologics, we have found the ideal complement for our European plasma protein business and have become a global player in the industry," said Gregor Schulz, chairman of the management board of Biotest. "We have an immediate share in the highly attractive and growing US plasma protein market and are substantially expanding our capacities, extending our product range and consolidating our clinical development portfolio," he added.